- Home
- CFR vs JAZZ Comparison
CFR vs JAZZ Comparison
Compare CFR & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFR
- JAZZ
- Stock Information
- Founded
- CFR 1868
- JAZZ 2003
- Country
- CFR United States
- JAZZ Ireland
- Employees
- CFR N/A
- JAZZ N/A
- Industry
- CFR Major Banks
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- CFR Finance
- JAZZ Health Care
- Exchange
- CFR Nasdaq
- JAZZ Nasdaq
- Market Cap
- CFR 6.8B
- JAZZ 6.5B
- IPO Year
- CFR N/A
- JAZZ 2007
- Fundamental
- Price
- CFR $139.27
- JAZZ $121.65
- Analyst Decision
- CFR Hold
- JAZZ Buy
- Analyst Count
- CFR 13
- JAZZ 14
- Target Price
- CFR $121.92
- JAZZ $173.57
- AVG Volume (30 Days)
- CFR 629.8K
- JAZZ 653.4K
- Earning Date
- CFR 10-31-2024
- JAZZ 11-06-2024
- Dividend Yield
- CFR 2.73%
- JAZZ N/A
- EPS Growth
- CFR N/A
- JAZZ 458.10
- EPS
- CFR 8.07
- JAZZ 7.04
- Revenue
- CFR $1,964,467,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- CFR N/A
- JAZZ $7.43
- Revenue Next Year
- CFR $2.73
- JAZZ $6.39
- P/E Ratio
- CFR $17.26
- JAZZ $17.29
- Revenue Growth
- CFR 0.42
- JAZZ 5.23
- 52 Week Low
- CFR $94.09
- JAZZ $99.06
- 52 Week High
- CFR $144.89
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- CFR 63.58
- JAZZ 59.73
- Support Level
- CFR $137.72
- JAZZ $108.74
- Resistance Level
- CFR $144.89
- JAZZ $128.99
- Average True Range (ATR)
- CFR 4.29
- JAZZ 2.99
- MACD
- CFR 0.29
- JAZZ 1.14
- Stochastic Oscillator
- CFR 74.09
- JAZZ 63.75
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost Bankers is a financial holding company, The company offer commercial and consumer banking services, as well as trust and investment management, insurance, brokerage, mutual funds, leasing, treasury management, capital markets advisory and item processing services across Texas in the Austin, Corpus Christi, Dallas, Fort Worth, Houston, Permian Basin, Rio Grande Valley, and San Antonio regions.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.